New York, NY (PRWEB) January 04, 2013
The prescription drug resource center DrugRisk.com is advising women who use the vaginal ring contraceptive NuvaRing that, amid warnings about risks of blood clots and news of injury claims filed by those affected, Merck has reported reduced sales of the devices.
The goal of DrugRisk is to improve patient safety through education of the latest drug warnings, recalls, studies and litigation news. In some cases lower sales reports can indicate that patients have heeded warnings and switched to alternatives after consulting with their doctor, explains DrugRisk representative Ryan Mayer.
The resource center previously reported that as many as 1,028 patients have filed a NuvaRing lawsuit claiming blood clots in a special federal court in Missouri.* The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.
Experts have related vaginal rings like NuvaRing to higher blood clot risks than with traditional birth control pills.
The British Medical Journal published a Danish study on May 10, 2012 linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives. On June 14, 2012, the New England Journal of Medicine also published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.
Now, Merck has disclosed in its Third Quarter 2012 Financial Report that sales of NuvaRing decreased 2% since the same period in 2011, from $159 million to $156 million.**
Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.
Due to the specialized nature of federal MDL drug injury cases, the DrugRisk Center only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
**Merck Supplement to 3Q 2012 Earnings Release, Pg. 7, Key Product Sales